US 12,152,037 B2
Crystalline succinate salt of 6-(6-aminopyrazin-2-yl)-N-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine as a Syk inhibitor
Patricia Andres, West Lafayette, IN (US); Peter C. Fung, San Mateo, CA (US); Pierre Giguere, Edmonton (CA); Chiajen Lai, Livermore, CA (US); Craig Stewart, Natick, MA (US); Jing Teng, West Lafayette, IN (US); Duong D. Tran, Edmonton (CA); Iva Trantcheva, Sonoma, CA (US); and Brian Yarmuch, Sherwood Park (CA)
Assigned to Kronos Bio, Inc., San Mateo, CA (US)
Filed by Kronos Bio, Inc., San Mateo, CA (US)
Filed on May 19, 2022, as Appl. No. 17/664,193.
Application 17/664,193 is a division of application No. 16/796,479, filed on Feb. 20, 2020, granted, now 11,339,168.
Claims priority of provisional application 62/809,337, filed on Feb. 22, 2019.
Prior Publication US 2023/0098309 A1, Mar. 30, 2023
Int. Cl. A61K 31/4985 (2006.01); C07D 487/04 (2006.01)
CPC C07D 487/04 (2013.01) [C07B 2200/13 (2013.01)] 7 Claims
 
1. A crystalline form of Compound I:

OG Complex Work Unit Chemistry
wherein the crystalline form is succinate Form I; and
wherein crystalline succinate Form I is characterized by an X-ray powder diffractogram comprising characteristic peaks (°2θ) at 15.2°±0.2°2θ, 18.0°±0.2°2θ, and 20.0°±0.2°2θ.
 
5. A pharmaceutical composition comprising the crystalline form according to claim 1 and a pharmaceutically acceptable excipient.